The estimated Net Worth of Jacqueline Scanlan is at least $6.08 million dollars as of 9 August 2023. Ms. Scanlan owns over 17,008 units of Haemonetics stock worth over $289,872 and over the last 7 years she sold HAE stock worth over $4,252,660. In addition, she makes $1,541,330 as Senior Vice President - Human Resources at Haemonetics.
Jacqueline has made over 24 trades of the Haemonetics stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 17,008 units of HAE stock worth $501,396 on 9 August 2023.
The largest trade she's ever made was selling 17,008 units of Haemonetics stock on 9 August 2023 worth over $501,396. On average, Jacqueline trades about 2,823 units every 62 days since 2018. As of 9 August 2023 she still owns at least 4,001 units of Haemonetics stock.
You can see the complete history of Ms. Scanlan stock trades at the bottom of the page.
Jacqueline D. Scanlan serves as Senior Vice President - Human Resources of the Company. Prior to joining the Company, Ms. Scanlan served as Corporate Vice President, Human Resources, North America at Novo Nordisk, a global healthcare company specializing in diabetes care, from October 2014 to October 2016. In that role, Ms. Scanlan led all aspects of the organization and people strategy for North America, and served as a key member of the executive team. Her responsibilities included organization development as well as change and talent management. Prior to Novo Nordisk, from October 2007 to October 2014, Ms. Scanlan held various human resources leadership roles at Campbell Soup Company, a global producer of prepared and fresh foods and beverages, where she was responsible for human resources in the International Business and Corporate functions, as well as Global Talent Management and Organizational Effectiveness. Earlier in her career, Ms. Scanlan held human-resource roles at Bristol-Myers Squibb and DuPont Pharmaceuticals Company and was a consultant at Accenture. Ms. Scanlan received a Bachelor of Arts in Political Science from St. Joseph’s University and a Master of Science in Organizational Dynamics from the University of Pennsylvania.
As the Senior Vice President - Human Resources of Haemonetics, the total compensation of Jacqueline Scanlan at Haemonetics is $1,541,330. There are 4 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of $9,398,200.
Jacqueline Scanlan is 47, she's been the Senior Vice President - Human Resources of Haemonetics since 2017. There are 13 older and no younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Jacqueline's mailing address filed with the SEC is C/O FMC CORPORATION, 2929 WALNUT STREET, PHILADELPHIA, PA, 19104.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy et Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: